Invesaro

Stocks Comparison

Intellia Therapeutics vs QuidelOrtho: revenue, profit, margins and growth compared

Intellia Therapeutics brought in $67.7M of revenue in fiscal 2025, QuidelOrtho $2.7B in fiscal 2025. Revenue changed by +16.9% at Intellia Therapeutics and -1.9% at QuidelOrtho on the year before, so Intellia Therapeutics grew faster. Intellia Therapeutics kept -609.9% of its revenue as net profit, QuidelOrtho -41.5%. Free cash flow was -$395.9M at Intellia Therapeutics and -$83M at QuidelOrtho.

Side by side, latest fiscal year

NTLAQDEL
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 28, 2025)
Revenue$67.7M$2.7B
Revenue growth+16.9%-1.9%
Net income-$412.7M-$1.1B
Net margin-609.9%-41.5%
Free cash flow-$395.9M-$83M
Free cash flow margin-585.0%-3.0%
Earnings per share (diluted)-$3.81-$16.69
Cash$155.5M$169.8M
Debtn/a$2.7B
Price to earningsn/an/a
Market value$1.6B$750.2M
Dividend yieldn/an/a
Rank by revenue in sector#339 of 523 · Health care#90 of 523 · Health care

Over the years

Revenue
NTLA FY2018: $30.4MNTLA FY2019: $43.1MNTLA FY2020: $58MNTLA FY2021: $33.1MNTLA FY2022: $52.1MNTLA FY2023: $36.3MNTLA FY2024: $57.9MNTLA FY2025: $67.7MQDEL FY2020: $1.7BQDEL FY2022: $1.7BQDEL FY2022: $3.3BQDEL FY2023: $3BQDEL FY2024: $2.8BQDEL FY2025: $2.7BFY18FY19FY20FY21FY22FY23FY24FY25
NTLA $67.7MQDEL $2.7B
Net income
NTLA FY2018: -$85.3MNTLA FY2019: -$474.2MNTLA FY2020: -$134.2MNTLA FY2021: -$267.9MNTLA FY2022: -$474.2MNTLA FY2023: -$481.2MNTLA FY2024: -$519MNTLA FY2025: -$412.7MQDEL FY2020: $810.3MQDEL FY2022: $704.2MQDEL FY2022: $548.7MQDEL FY2023: -$10.1MQDEL FY2024: -$2.1BQDEL FY2025: -$1.1BFY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$412.7MQDEL -$1.1B
Net margin
NTLA FY2018: -280.4%NTLA FY2019: -1,100.1%NTLA FY2020: -231.5%NTLA FY2021: -810.5%NTLA FY2022: -909.8%NTLA FY2023: -1,326.5%NTLA FY2024: -896.8%NTLA FY2025: -609.9%QDEL FY2020: 48.8%QDEL FY2022: 41.5%QDEL FY2022: 16.8%QDEL FY2023: -0.3%QDEL FY2024: -73.7%QDEL FY2025: -41.5%FY18FY19FY20FY21FY22FY23FY24FY25
NTLA -609.9%QDEL -41.5%
Revenue growth
NTLA FY2019: +41.6%NTLA FY2020: +34.5%NTLA FY2021: -43.0%NTLA FY2022: +57.7%NTLA FY2023: -30.4%NTLA FY2024: +59.6%NTLA FY2025: +16.9%QDEL FY2022: +2.2%QDEL FY2022: +92.3%QDEL FY2023: -8.2%QDEL FY2024: -7.2%QDEL FY2025: -1.9%FY19FY20FY21FY22FY23FY24FY25
NTLA +16.9%QDEL -1.9%
Free cash flow
NTLA FY2018: -$67.6MNTLA FY2019: -$110MNTLA FY2020: -$53.5MNTLA FY2021: -$237.8MNTLA FY2022: -$346.8MNTLA FY2023: -$408.1MNTLA FY2024: -$354.7MNTLA FY2025: -$395.9MQDEL FY2020: $564.8MQDEL FY2022: $513.1MQDEL FY2022: $744.4MQDEL FY2023: $70.9MQDEL FY2024: -$112.1MQDEL FY2025: -$83MFY18FY19FY20FY21FY22FY23FY24FY25
NTLA -$395.9MQDEL -$83M

Fiscal years as each company reports them; the two may end in different months.

Questions about Intellia Therapeutics and QuidelOrtho

Which is bigger by revenue, Intellia Therapeutics or QuidelOrtho?

QuidelOrtho is bigger by revenue: $2.7B in fiscal 2025, against $67.7M for Intellia Therapeutics in fiscal 2025.

Which keeps more of its revenue as profit, Intellia Therapeutics or QuidelOrtho?

Intellia Therapeutics had a net margin of -609.9% in fiscal 2025; QuidelOrtho had -41.5% in fiscal 2025.

Which grew revenue faster, Intellia Therapeutics or QuidelOrtho?

In their latest fiscal years revenue changed by +16.9% at Intellia Therapeutics and -1.9% at QuidelOrtho.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies